Novartis AG (NYSE:NVS; SIX:NOVN), a Swiss-based biopharmaceutical company, has announced its intention to spin out its Alcon eye care business but will retain the pharmaceutical… Read More »Novartis announces spin out of Alcon unit to consolidate focus on pharmaceutical products.
Ophthotech Corporation (NASDAQ: OPHT), a US-based biopharmaceutical company focused on the development of retinal disease therapies, has announced the execution of agreements with both the… Read More »Ophthotech Corporation (NASDAQ:OPHT) announce agreements with two US universities to progress gene therapy for autosomal dominant retinitis pigmentosa (adRP)
Clearside Biomedical Inc. (NASDAQ:CLSD), head-quartered in Alpharetta, Ga., USA, have announced the results of a Phase II clinical study investiagting the use of triamcinolone acteonide… Read More »Clearside Biomedical Inc. study fails to show clinical significance of triamcinolone acetonide plus anti-VEGF treatment
Novartis AG (NYSE: NVS; SIX: NOVN) has recently launched a new app, “FocalView”, aiming to provide “an opportunity for patients to participate in ophthalmology clinical… Read More »Novartis AG (NYSE: NVS; SIX: NOVN) sees the addition of virtual technology to clinical trials as a significant component for future drug development and surveillance.
ProQR Therapeutics N.V. (NASDAQ: PRQR) and the US charity Foundation Fighting Blindness (FFB) have announced a new partnership to accelerate the development of a novel… Read More »Dutch company ProQR Therapeutics N.V. (NASDAQ: PRQR) and US Foundation Fighting Blindness enter a collaborative partnership to develop a treatment for Usher syndrome
GenSight Biologics S.A. (Euronext: SIGHT) has announced topline results from the company’s Phase III “REVERSE” clinical study of an experimental gene therapy, ”GS010”, designed… Read More »Topline data from GenSight’s Phase III REVERSE study provide an unusual and unexpected outcome
According to The Scientist publication, French universities and research organisations have cancelled their subscription to almost 2,000 academic journals managed by Springer, a German-based global… Read More »Business of academic publishing under pressure following French universities’ decision to cancel Springer journals subscriptions
Homology Medicine Inc, a gene editing company based in Massachusetts, USA, has announced a $100M IPO on the US NASDAQ. The company uses its technology… Read More »Homology Medicine Inc., with plans to develop AAV gene therapies for ophthalmic disease, announce plans for a $100M IPO on the US NASDAQ
GenSight Biologics S.A. (Euronext: SIGHT) has announced the publication of the company’s clinical results from a Phase I/II study and long-term follow-up of an experimental… Read More »French company GenSight Biologics announces positive results for its Phase I/II clinical study of a gene therapy treatment for Leber Hereditary Optic Neuropathy
Spark Therapeutics Inc. (NASDAQ:ONCE) have announced that the company has entered into a licensing and supply agreement for investigational voretigene neparvovec, branded in the US… Read More »Novartis AG (NYSE: NVS; SIX: NOVN) attains ex-US rights to develop and commercialize new gene therapy treatment for Leber’s congenital amaurosis (LCA).